Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLP-1-AMX
- Development stage
- Preclinical
- Lead developer
- KWHC
- Modality
- Peptides, Small Molecules
01
Overview
GLP-1-AMX is a preclinical drug candidate being developed by KWHC (KWEHEALTH). It is characterized as a novel glucagon-like peptide-1 (GLP-1) analog, which may be formulated as either a peptide or a small molecule. The drug is designed to function as an agonist of the Glucagon-like peptide 1 receptor (GLP-1R), a target primarily associated with the treatment of metabolic disorders such as type 2 diabetes and obesity. The "AMX" component of the name, as specified in the provided context, refers to amoxicillin, suggesting a combination or conjugation of the GLP-1 analog with this beta-lactam antibiotic. This candidate is part of KWHC's broader focus on regenerative therapies and perinatal tissue-derived products. It is currently in the early research and preclinical development stage.
- Other names
- glucagon-like peptide-1 + amoxicillinGLP-1-AMXGLP1-AMXGLP 1-AMX
02
Targets
GLP1R (GLP-1R)PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on GLP-1-AMX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLP-1-AMX.